Clinical Trials

316 enrolled

Head & Neck

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms

NCT06567782 2026-05-22

AZUR-4

120 enrolled

Colonic Neoplasms

NCT04165772 2026-05-13

Study of Induction PD-1 Blockade in Subjects With Locally Advanced Mismatch Repair Deficient Solid Tumors

212 enrolled

Rectal Neoplasms

NCT04584255 2026-05-13

Niraparib + Dostarlimab In BRCA Mutated Breast Cancer

62 enrolled

Breast

Breast Neoplasms

NCT04774419 2026-05-13

Radiation and TSR-042 (Dostarlimab) in People With Endometrial Cancer After They Receive Surgery

62 enrolled

Endometrial Neoplasms

NCT04313504 2026-05-07

Study Evaluating the Efficacy of Niraparib and Dostarlimab (TSR-042) in Recurrent/Metastatic HNSCC

10 enrolled 9 charts

Head & Neck

Head and Neck Neoplasms

NCT01042379 2026-05-06

I-SPY

5,000 enrolled

BreastSarcoma

Pathologic Complete Response, Breast Neoplasms, Hemangiosarcoma, Neoplasms, Triple Negative Breast Neoplasms

NCT06023862 2026-05-06

DOVE

198 enrolled

Uterine Cervical Neoplasms, Ovarian Neoplasms, Vaginal Neoplasms, Vulvar Neoplasms, Endometrial Neoplasms, Adenocarcinoma, Clear Cell

NCT07408063 2026-04-29

BeeHive

30 enrolled

Head & Neck

Squamous Cell Carcinoma of Head and Neck

NCT04701307 2026-04-22

Niraparib and Dostarlimab for the Treatment of Small Cell Lung Cancer and Other High-Grade Neuroendocrine Carcinomas

48 enrolled

EndocrineThoracic

Lung Neoplasms, Carcinoma, Neuroendocrine, Small Cell Lung Carcinoma

NCT03680508 2026-04-02

TSR-022 (Anti-TIM-3 Antibody) and TSR-042 (Anti-PD-1 Antibody) in Patients With Liver Cancer

42 enrolled

Carcinoma, Hepatocellular

NCT06830239 2026-02-12

Superhero

10 enrolled

Colonic Neoplasms

NCT04068753 2026-02-10

STAR

66 enrolled

Uterine Cervical Neoplasms

NCT05700721 2026-02-05

Phase II Trial of the PARP Inhibitor Niraparib and PD-1 Inhibitor Dostarlimab in Patients With Advanced Cancers With Active Progressing Brain Metastases (STARLET)

Phase 2 Not yet recruiting

120 enrolled

CNS

Brain Neoplasms

NCT07381777 2026-02-02

IMMUNOSTAR

270 enrolled

Locally Advanced Rectal Cancer (LARC)

NCT07336147 2026-01-14

Dostarlimab, Cisplatin and Etoposide in Combination With Radiotherapy in Sandwich Sequence for Small Cell Neuroendocrine Cervical Carcinoma

45 enrolled

Uterine Cervical Neoplasms

NCT06238635 2026-01-13

Dostarlimab and Cobolimab in Advanced Cervical Cancer

66 enrolled

Uterine Cervical Neoplasms

NCT05565378 2026-01-08

A Platform Study of Novel Immunotherapy Combinations in Participants With Previously Untreated, Advanced/Metastatic Non-Small-Cell Lung Cancer

351 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT07108270 2025-12-22

A Study of Dostarlimab in Combination With Carboplatin-paclitaxel in Chinese Participants With Primary Advanced or Recurrent Endometrial Cancer (EC)

30 enrolled

Endometrial Neoplasms

NCT05526989 2025-12-04

Study of the Combination Dostarlimab With Niraparib In Patients With Penile Carcinoma

25 enrolled

Genitourinary

Penile Neoplasms

NCT06333314 2025-12-02

Pan-MSI-ACSE

GastrointestinalGenitourinaryHead & Neck

120 enrolled

EndocrineSarcoma

Neoplasm Metastasis, Neoplasms, Sarcoma, Adrenocortical Carcinoma, Carcinoma, Neuroendocrine

NCT04779151 2025-12-01

NIRADO

Phase 2 Terminated

51 enrolled

Biliary Tract Neoplasms, Carcinoma, Renal Cell, Head and Neck Neoplasms

NCT06640049 2025-11-17

China AZUR-1

23 enrolled

Rectal Neoplasms

NCT04139902 2025-10-15

Neoadjuvant PD-1 Inhibitor Dostarlimab (TSR-042) vs. Combination of Tim-3 Inhibitor Cobolimab (TSR-022) and PD-1 Inhibitor Dostarlimab (TSR-042) in Melanoma

48 enrolled

Dermatologic

Melanoma

NCT04837209 2025-10-01

NADiR

Phase 2 Not yet recruiting

32 enrolled

Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT07115927 2025-08-19

RODEO

40 enrolled

Endometrial Neoplasms

NCT04409002 2025-08-15

Niraparib + Dostarlimab + RT in Pancreatic Cancer

18 enrolled 11 charts

Pancreatic Neoplasms

NCT04581824 2025-08-08

Efficacy Comparison of Dostarlimab Plus Chemotherapy Versus Pembrolizumab Plus Chemotherapy in Participants With Metastatic Non-squamous Non-small Cell Lung Cancer (NSCLC)

Phase 2 Terminated

243 enrolled 21 charts

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT04493060 2025-08-07

Niraparib and Dostarlimab for the Treatment of Germline or Somatic BRCA1/2 and PALB2 Mutated Metastatic Pancreatic Cancer

22 enrolled 17 charts

Pancreatic Neoplasms

NCT06317311 2025-07-25

RUBY-J

41 enrolled

Carcinoma, Endometrial Neoplasms

NCT03574779 2025-07-15

OPAL

77 enrolled 8 charts

Ovarian Neoplasms

NCT06926673 2025-07-03

Platform Trial of Novel Regimens Versus Standard of Care (SoC) in Participants With Non-small Cell Lung Cancer (NSCLC) - Sub-study 3

62 enrolled 36 charts

Tumor-Agnostic

Neoplasms

NCT03739710 2025-06-15

Platform Trial of Novel Regimens Versus Standard of Care (SoC) in Participants With Non-small Cell Lung Cancer (NSCLC)

Phase 2 Not yet recruiting

175 enrolled 5 charts

Thoracic

Carcinoma, Non-Small-Cell Lung, Neoplasms

NCT07013851 2025-06-10

NADIA

25 enrolled

GynecologicOther solid neoplasm

MMRd/MSI-H Stage II-III Endometrial Cancer

NCT05239546 2025-05-25

NAIO

25 enrolled

Colonic Neoplasms

NCT03833479 2025-05-21

ATOMICC

134 enrolled

Uterine Cervical Neoplasms

NCT05126342 2025-04-06

Study to Estimate Efficacy of Combining Dostarlimab and Niraparib in Relapsed EOC After Treatment With PARPi

Phase 2 Withdrawn

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT06757244 2025-03-18

DOVIPA

35 enrolled

GastrointestinalOther solid neoplasm

Pancreatic Neoplasms

NCT06365970 2025-02-03

Niraparib and Dostarlimab for Patients With MMR-D/MSI-H Colorectal Cancers

Phase 2 Withdrawn

MMR-D/MSI-H Colorectal Cancers

NCT06278857 2024-12-03

SATELLITE

10 enrolled

Turcot syndrome, Endometrial Neoplasms

NCT05855811 2024-07-15

PREDOSTAR

400 enrolled

Neoplasms, Recurrence, Neoplasms, Second Primary

NCT04817956 2024-02-29

IMPRESS-N

3,000 enrolled

Tumor-Agnostic

Neoplasm Metastasis

NCT06059495 2024-02-05

DEWI

59 enrolled

Adenocarcinoma - GEJ

NCT04274023 2024-02-01

ACCeSs

Phase 2 Terminated

3 enrolled

Sarcoma

Sarcoma, Clear Cell

NCT03016338 2024-01-30

Study of Niraparib and TSR-042 in Recurrent Endometrial Cancer

Phase 2 Unknown

51 enrolled

Endometrial Neoplasms

NCT05065021 2024-01-17

Using Genetic Profile to Determine the Treatment for Patients With Ovarian Cancer Who Previously Received a PARP-inhibitor

Phase 2 Unknown

40 enrolled

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT03308942 2023-10-16

Effects of Single Agent Niraparib and Niraparib Plus Programmed Cell Death-1 (PD-1) Inhibitors in Non-Small Cell Lung Cancer Participants

Other solid neoplasmThoracic

53 enrolled 35 charts

Tumor-Agnostic

Neoplasms

NCT04940637 2023-05-12

UNITO-001

Phase 2 Unknown

70 enrolled

Lung Neoplasms, Mesothelioma

NCT05751629 2023-04-21

COHORT-A

41 enrolled 17 charts